141 results
Page 5 of 8
PRE 14A
w8dlx7ady ku1p3ks
14 Apr 21
Preliminary proxy
4:00pm
10-K
EX-31.1
m933w3tbg9jqu2ecn
1 Mar 21
Annual report
12:00am
10-K
EX-10.20
4o7nqmsy3
1 Mar 21
Annual report
12:00am
10-K
EX-10.21
h6s iez8xwww7c6
1 Mar 21
Annual report
12:00am
10-K
vno hb8c7h7ojvd7
1 Mar 21
Annual report
12:00am
10-K
EX-10.32
wp9vk8qnzcyb9otc0c
1 Mar 21
Annual report
12:00am
10-K
EX-10.33
ffvpkif33so0wjhh2
1 Mar 21
Annual report
12:00am
10-K
EX-31.2
29umd
1 Mar 21
Annual report
12:00am
10-K
EX-10.22
4sy85y2p52
1 Mar 21
Annual report
12:00am
10-K
EX-4.5
2rpq8b ah
1 Mar 21
Annual report
12:00am
8-K
hb58dyb
11 Jan 21
Zai Lab Secures Exclusive Right to Develop and Commercialize TPX-0022, Turning
6:52am
8-K
naqow hd5
6 Jan 21
Zai Lab granted exclusive rights to develop and commercialize efgartigimod in Greater China
4:08pm
6-K
EX-99.1
zqrwoidydhp57yxjxgp
1 Dec 20
Zai Lab Appoints Alan Sandler, M.D., as President, Head of Global Development, Oncology
7:30am
UPLOAD
j8q6 vqgcaofj4
30 Oct 20
Letter from SEC
12:00am
424B5
3k5 sb48r
23 Sep 20
Prospectus supplement for primary offering
8:06am
6-K
EX-1.1
4srdozgy
21 Sep 20
Current report (foreign)
4:15pm
20-F/A
EX-12.2
d1r9mu2jz ctbibepk9
18 Sep 20
Annual report (foreign) (amended)
4:01pm
20-F/A
EX-12.1
g8raw
18 Sep 20
Annual report (foreign) (amended)
4:01pm
424B5
h06omnt1
16 Sep 20
Prospectus supplement for primary offering
7:24am
6-K
EX-99.1
9wq424 1gw0y
11 Sep 20
Current report (foreign)
8:16am